These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21179615)

  • 21. Restless legs syndrome: differential diagnosis and management with pramipexole.
    Brindani F; Vitetta F; Gemignani F
    Clin Interv Aging; 2009; 4():305-13. PubMed ID: 19750232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnosis and symptom rating scale of restless legs syndrome].
    Inoue Y
    Brain Nerve; 2009 May; 61(5):533-8. PubMed ID: 19514513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
    Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
    Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome.
    Esteve V; Carneiro J; Salazar G; Pou M; Tapia I; Fulquet M; Duarte V; Saurina A; Moreno F; Ramírez de Arellano M
    Nefrologia (Engl Ed); 2018; 38(1):79-86. PubMed ID: 29198453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. D3 receptor agonist efficacy in restless legs syndrome.
    Casoni F; Galbiati A; Ferini-Strambi L
    Adv Pharmacol; 2019; 84():21-35. PubMed ID: 31229173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease).
    Elshoff JP; Hudson J; Picchietti DL; Ridel K; Walters AS; Doggett K; Moran K; Oortgiesen M; Ramirez F; Schollmayer E
    Sleep Med; 2017 Apr; 32():48-55. PubMed ID: 28366342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Saletu B; Trenkwalder C; Sommerville KW; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Mar; 9(3):228-39. PubMed ID: 17553743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioids for restless legs syndrome.
    de Oliveira CO; Carvalho LB; Carlos K; Conti C; de Oliveira MM; Prado LB; Prado GF
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD006941. PubMed ID: 27355187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restless legs syndrome in 2004.
    Sonka K; Kemlink D
    Prague Med Rep; 2004; 105(4):337-56. PubMed ID: 15822631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restless legs syndrome: pathophysiology and modern management.
    Nagandla K; De S
    Postgrad Med J; 2013 Jul; 89(1053):402-10. PubMed ID: 23524988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of restless legs syndrome (RLS) on sleep.
    Bogan RK
    Neuropsychiatr Dis Treat; 2006 Dec; 2(4):513-9. PubMed ID: 19412499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rotigotine for restless legs syndrome.
    Davies S
    Drugs Today (Barc); 2009 Sep; 45(9):663-8. PubMed ID: 19956807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Restless legs syndrome].
    Lai SC; Chen RS
    Acta Neurol Taiwan; 2008 Mar; 17(1):54-65. PubMed ID: 18564830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Restless legs syndrome - a review].
    Sveinsson OA; Sigurdsson AP
    Laeknabladid; 2012 Jan; 98(1):33-7. PubMed ID: 22253081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Update on the treatment of restless legs syndrome].
    Konno M; Uchiyama M
    Brain Nerve; 2009 May; 61(5):549-57. PubMed ID: 19514515
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.